WAYNE, Pa.--(BUSINESS WIRE)--Encorium Group, Inc. (Nasdaq: ENCO), a leader in the design, development, and management of complex clinical trials and patient registries for many of the world's leading pharmaceutical and biotechnology companies, today announced that the Company signed multiple new contracts with an aggregate value of approximately $4.0 million during its second quarter ended June 30, 2007. These contracts, which are in addition to the $8.5 million of signed contracts announced over the past four weeks, are for developmental support of new clinical trials and various changes-of-scope for existing studies. The contracts are with multiple clients and are across numerous therapeutic areas including cardiovascular diseases, oncology, diabetes, infectious diseases, and immunology/vaccines. Encorium will provide a variety of services, including consulting and trial design, project management, field monitoring, data management, financial management, and quality assurance. Revenue recognition for these contracts principally began in the current third quarter and will occur on a proportional performance basis as services are performed on each project.